Full text
Earnings transcript
Read the complete earnings call transcript.
BMRN
BioMarin Pharmaceutical Inc.
$55.5
-1.74
(-3.04%)
| Exchange: | NASDAQ |
| Market Cap: | 10.674B |
| Shares Outstanding: | 22.488M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Alexander Hardy | |||||
| Full Time Employees: | 3040 | |||||
| Address: |
| |||||
| Website: | https://www.biomarin.com |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 2,419,226 | 2,853,915 | 3,221,253 |
| Gross Profit | 1,887,164 | 2,273,680 | 2,484,425 |
| EBITDA | 306,773 | 650,528 | 572,936 |
| Operating Income | 185,774 | 484,214 | 533,477.999 |
| Net Income | 167,645 | 426,859 | 348,901 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 6,841,603 | 6,988,940 | 7,594,022 |
| Total Liabilities | 1,890,054 | 1,330,950 | 1,507,023 |
| Total Stockholders Equity | 4,951,549 | 5,657,990 | 6,086,999 |
| Total Debt | 1,095,751 | 602,712 | 597,176 |
| Cash and Cash Equivalents | 755,127 | 942,842 | 1,311,679 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 159,259 | 572,841 | 827,994 |
| Capital Expenditure | -107,611 | -97,418 | -103,038 |
| Free Cash Flow | 51,648 | 475,423 | 724,956 |
| Net Income | 167,645 | 426,859 | 348,901 |
| Net Change in Cash | 30,596 | 187,715 | 368,837 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 4,889,531.018 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 5,286,087.523 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 5,089,173.692 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 669,769.142 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 724,089.548 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 697,116.244 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 1,583,086.070 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 1,752,067.178 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 1,668,158.936 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 1,880,433.496 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 2,032,942.629 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 1,957,212.797 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 8.450 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 8.880 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 8.020 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 4 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 6 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Revenue Performance: BMRN has demonstrated consistent revenue growth as reported in recent income statements, reflecting robust demand for its specialized biopharmaceutical products. This growth aligns with industry trends in biotechnology, particularly in rare disease treatments.
- Solid Financial Position: The company maintains a healthy balance sheet, with significant cash and cash equivalents and total current assets outweighing current liabilities, as per the latest balance sheet data. This liquidity supports ongoing operations and potential investments in R&D.
- High Gross Profit Margin: Key metrics indicate a strong gross profit margin (TTM), showcasing BMRN's ability to manage production costs effectively and maintain profitability in a competitive sector.
- Focused Innovation: As highlighted in earnings call transcripts, BMRN continues to prioritize innovation in its product pipeline, with strategic investments in therapies for rare genetic disorders, positioning it as a leader in niche markets.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates BMRN intrinsic value between $35.56 – $167.17 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about BMRN valuation
Is BioMarin Pharmaceutical Inc. (BMRN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for BioMarin Pharmaceutical Inc. (BMRN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is BMRN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BMRN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is BMRN’s P/E ratio?
You can see BMRN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for BMRN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is BMRN a good long-term investment?
Whether BMRN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
BMRN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-3.04
Trading Metrics:
| Open: | 56.44 | Previous Close: | 57.24 | |
| Day Low: | 54.54 | Day High: | 56.55 | |
| Year Low: | 50.76 | Year High: | 66.49 | |
| Price Avg 50: | 58.37 | Price Avg 200: | 56.53 | |
| Volume: | 2.203M | Average Volume: | 2.022M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeBMRN full analysis
Welcome to MARKETSNAP’s SWOT analysis for BioMarin Pharmaceutical, also known by its ticker BMRN. If you’re a long-term investor looking to dig into the biotech space, you’ve come to the right place. Today, we’re breaking down BioMarin, a company that’s carving out a niche in the biotechnology industry, focusing on therapies for rare genetic diseases. Let’s unpack what makes this company tick, dive into recent developments, and analyze its strengths, weaknesses, opportunities, and threats—all with an eye on long-term wealth-building…
